Table 5.
Recommendations on the use of calcitonin gene-related peptide monoclonal antibodies for the prevention of episodic and chronic migraine
| Setting | Drug | Recommendation | Quality of evidence | Strength of the recommendation |
|---|---|---|---|---|
| Migraine prevention in patients with episodic migraine | Eptinezumab 1000 mg quarterly | Suggested | ⨁⨁◯◯ LOW | ↑? Weak |
| Erenumab 70 mg monthly | Recommended | ⨁⨁⨁⨁ HIGH | ↑↑ Strong | |
| Erenumab 140 mg monthly | Recommended | ⨁⨁⨁◯ MEDIUM | ↑↑Strong | |
| Fremanezumab 225 mg monthly | Recommended | ⨁⨁⨁⨁ HIGH | ↑↑ Strong | |
| Fremanezumab 675 mg quarterly | Recommended | ⨁⨁⨁◯ MEDIUM | ↑↑Strong | |
| Galcanezumab 240 mg loading dose + 120 mg monthly | Recommended | ⨁⨁⨁⨁ HIGH | ↑↑ Strong | |
| Galcanezumab 240 mg monthly | Recommended | ⨁⨁⨁⨁ HIGH | ↑↑ Strong | |
| Migraine prevention in patients with chronic migraine | Erenumab 70 mg monthly | Recommended | ⨁⨁⨁◯ MEDIUM | ↑↑Strong |
| Erenumab 140 mg monthly | Recommended | ⨁⨁⨁◯ MEDIUM | ↑↑Strong | |
| Fremanezumab 675 mg quarterly | Recommended | ⨁⨁⨁◯ MEDIUM | ↑↑Strong | |
| Fremanezumab 675 mg loading dose + 225 mg monthly | Recommended | ⨁⨁⨁⨁ HIGH | ↑↑ Strong | |
| Galcanezumab 240 mg loading dose + 120 mg monthly | Recommended | ⨁⨁⨁◯ MEDIUM | ↑↑Strong | |
| Galcanezumab 240 mg monthly | Recommended | ⨁⨁⨁◯ MEDIUM | ↑↑Strong |
Symbols depict the strength of the recommendation according to the GRADE system. The quality of evidence for the Galcanezumab study was changed from medium to high